



09:00 - 09:10 **Opening: Mircea Dediu, Laura Mazilu**

09:10 - 11:10 **Chairs: Mircea Dediu, Laura Mazilu**

09:10 - 09:30 **Should we still consider classical surgery first followed by adjuvant treatment in early stage NSCLC?**
Tudor Ciuleanu

09:30 - 09:50 **Stage III NSCLC – Navigating the borderline between Neoadjuvant Strategy and Definitive Chemoradiotherapy**
Dana Clement

09:50 - 10:10 **How to integrate ctDNA assessment in the management of NSCLC**
Șerban Negru

10:10 - 10:30 **Re-treatment with immunotherapy: any available evidences?**
Laura Mazilu

10:30 - 10:50 **Managing Immune-Related Adverse Events: A Practical Approach**
Amedeia Niță

10:50 - 11:10 **Addressing the KRAS mutation targeted treatment in NSCLC**
Răzvan Ovidiu Curcă

11:10 - 11:30 **Coffee Break**

11:30 - 12:00 **MSD SYMPOSIUM**
KEYTRUDA, the key to more possibilities for patients with NSCLC in early-stage disease
Dana Clement, Mircea Dediu



12:00 - 12:20

MERCK SYMPOSIUM

Teptotinib, a step forward in managing NSCLC

Mircea Dediu

12:20 - 12:35

ACCORD SYMPOSIUM

Bone Metastases in Lung Cancer: Clinical Challenges and Emerging Therapeutic Opportunities in the Era of Immunotherapy and Modern Multimodal Approaches

Mircea Dediu

12:35 - 12:50

PFIZER SYMPOSIUM

Start strong in the first line for ALK+ NSCLC: the role and importance of Lorlatinib

Tudor Ciuleanu

12:50 - 13:10

JOHNSON & JOHNSON SYMPOSIUM

Rybrent® redefines the management of patients with EGFR+ NSCLC with exon insertion

Tudor Ciuleanu

13:10 - 13:40

ROCHE SYMPOSIUM

Tecentriq® - Redefining the standard of care for treatment of ES-SCLC

Paul Kubelac

13:40 - 13:45

Break

13:45 - 14:15

WORKING LUNCH - MEDISON SYMPOSIUM

From detection to clinical decision: the critical role of MDT collaboration in lung cancer

Chair: Laura Mazilu

Șerban Negru, Cristian Oancea, Ovidiu Pop

14:15 - 14:25

Break



14:25 - 15:25 *Chairs: Dana Clement, Mircea Dediu*

14:25 - 14:45 **The Role of Psychological Support in Lung Cancer**
Ramona Schenker

14:45 - 15:05 **Genomic Signature of Lung Cancer – Liquid Biopsy and Precision Medicine**
Viorica Rădoi

15:05 - 15:25 **Overcoming acquired resistance to osimertinib based therapy in EGFR mutant NSCLC**
Dana Clement

15:25 - 15:45 **Coffee Break**

15:45 - 16:15 **MEDISON SYMPOSIUM**
Unlock new Horizons with Libtayo
Chair: Michael Schenker

From guideline to clinical practice - Defining the first move with Libtayo
Răzvan Ovidiu Curcă & Mircea Dediu

Unlocking Insights: Clinical case experience with Libtayo
Amedeia Niță

16:15 - 17:05 *Chairs: Mircea Dediu, Șerban Negru*

16:15 - 16:35 **Medical Treatment Opportunities for Lung Cancer in the Republic of Moldova**
Angela Munteanu

16:35 - 17:05 **Lung Cancer Screening Program: Pros and Cons**
Diana Ionescu



17:05 - 18:05 Tumour Board

- 17:05 - 17:25** **Critical Interval between neoadjuvant IO+CT and surgery (M1 BRA)**
Vladimir Preoteasa
- 17:25 - 17:45** **Metastatic NSCLC with PD-L1 \geq 50% - Choosing Between Immunotherapy Alone and Chemo-Immunotherapy in Clinical Practice**
Dana Clement
- 17:45 - 18:05** **Clinical Case presentation**
Vlad Vornicu
- 18:05 - 18:10** **Closing**
Mircea Dediu





09:00 - 11:00

ASTRAZENECA SATELITE SYMPOSIUM

Chair: Șerban Negru

09:00 - 09:15

Introduction

Șerban Negru

09:15 - 09:35

Optimising care across the resectable → borderline resectable NSCLC continuum

Giuseppe Banna

09:35 - 09:55

Overcoming resistance in mNSCLC: Treating Immune-Cold Mutations

Laura Mazilu

09:55 - 10:15

Reducing Recurrence rates in EGFR-Mutated Early-Stage NSCLC

Mircea Dediu

10:15 - 10:40

Optimizing first-line treatment for EGFR-mutated mNSCLC: balancing efficacy, toxicity, and survival endpoints

Alfredo Addeo

10:40 - 11:00

Integrating immunotherapy in SCLC: addressing unmet needs and future combinations

Răzvan Ovidiu Curcă

11:00 - 11:20

Coffee Break

11:20 - 12:00

Chairs: Mircea Dediu, Laura Mazilu

11:20 - 11:40

SCLC genomically homogenous but transcriptionally different: any clinical implications?

Michael Schenker

11:40 - 12:00

PCI for SCLC in the immune therapy era: anything new?

Giuseppe Banna



12:00 - 12:40 *Chairs: Laura Mazilu, Mircea Dediu*

12:00 - 12:20 **Emerging role of BiTE in ED-SCLC**
Laura Mazilu

12:20 - 12:40 **The Emerging Role and Clinical Trial Updates of ADCs in Lung Cancer Treatment**
Alfredo Addeo

12:40 - 13:40 **BMS SYMPOSIUM**
CheckMate 77T - The Journey Goes Further: Bridging Neoadjuvant Treatment Response to Perioperative Approach
Tudor Ciuleanu, Mircea Dediu, Mariano Provencio

13:40 - 14:30 **Lunch Break**

14:30 - 15:20 *Chair: Răzvan Ovidiu Curcă*

14:30 - 14:40 **Oncoresearch Platform – SNOMR connects Romanian oncology to European progress**
Răzvan Ovidiu Curcă

14:40 - 15:20 **RW data collection updates: retrospective and prospective initiatives in Romania**
Răzvan Ovidiu Curcă

15:20 - 16:00 *Debate Session*

15:20 - 16:00 **Neoadj vs perioperative strategy**
Mircea Dediu, Mariano Provencio

16:00 - 16:20 **Coffee Break**



16:20 - 17:40

ASTRAZENECA SYMPOSIUM

Chair: Laura Mazilu

IMFINZI: One IO regardless of resectability in non-mNSCLC
Giuseppe Banna

IMFINZI: One IO across the Entire SCLC Spectrum
Amedeia Niță

**Redefining Survival in FLAURA2: TAGRISSO +
chemotherapy is the First combination with the Highest
Demonstrated OS in EGFRm NSCLC**
Dana Clement

17:40 - 18:00

Updates in the mesothelioma managemnt
Lucian Miron

18:00 - 18:10

Closing
Mircea Dediu

#CuUnPas **Înainte**

